Alia Therapeutics is developing next-generation gene-editing therapies that utilize precise genome editing techniques to target and correct mutations responsible for rare genetic diseases. By focusing on the efficacy and durability of these treatments, the company aims to provide long-lasting cures that address the root causes of genetic disorders.

Arch Systems offers an AI-driven platform that integrates machine data and information systems to create a unified data model for electronics and discrete manufacturers. This technology enables real-time diagnostics and actionable insights, helping organizations recover up to 60% of quality and performance losses.

Binarly provides advanced binary risk intelligence for firmware and software supply chains without requiring source code access. The platform uses automated binary analysis to detect known and undisclosed vulnerabilities, malicious code, and transitive dependencies across binaries, firmware, and containers. This capability allows organizations to proactively manage risk, ensure compliance, and accelerate vulnerability resolution with high accuracy.

CIQ provides enterprise-grade support for industry-standard software solutions, ensuring reliability and performance for critical business operations. Their services address the challenges of system downtime and technical issues, enabling organizations to maintain operational continuity and efficiency.

Dymium provides a cloud infrastructure platform that enables enterprise development and IT teams to provision high‑performance CPU, GPU, and memory‑optimized virtual machines and managed block, file, and object storage through a self‑service portal and programmable APIs. The service includes auto‑scaling, integrated observability, security controls, and IaC integrations (Terraform, CloudFormation) to streamline deployment and lower operational overhead.

The startup has developed a minimally invasive method for the magnetic removal of kidney stone fragments, addressing the issue of residual fragments that can lead to renewed stone growth and complications in approximately 50% of patients. This technology eliminates the need for manual extraction of fragments, significantly reducing the risk of infections and the need for repeat treatments.

The startup offers a data protection and security platform that enables real-time access to data without the need for data movement or duplication, ensuring compliance with data governance policies. This solution effectively manages data access across diverse environments, including cloud technology and AI projects, while maintaining security and reducing operational costs.

Elisity provides an agent‑less, identity‑based microsegmentation platform that automatically discovers and classifies every user, workload, and device on existing network infrastructure, creating dynamic Zero Trust zones without hardware changes. The solution enforces least‑privilege access policies in real time, offers a simulation mode for testing, and generates automated compliance reports for standards such as HIPAA, IEC 62443, and PCI DSS, enabling rapid, enterprise‑scale deployment across IT, OT, and IoT environments.

Graphiant offers a Network-as-a-Service (NaaS) that provides secure, high-performance connectivity between hybrid cloud environments, network edges, and business partners. This solution enables enterprises to provision networks in minutes while achieving MPLS-level performance at a significantly lower total cost of ownership.

Inimmune develops novel immunotherapeutics utilizing Toll-like receptor (TLR) agonists to enhance immune responses in cancer and allergy treatments. Their clinical-stage assets, including INI-2004 and INI-4001, aim to provide disease-modifying effects for allergic rhinitis and cancer, addressing the need for more effective immunotherapy options.

The startup has developed a drug screening platform that utilizes pre-clinical assets to identify repurposing opportunities for small molecule cancer drugs. This technology enables healthcare providers to match patients with effective treatment options for underexplored cancer types, enhancing therapeutic outcomes.

Montara Therapeutics develops therapies for neurological diseases by leveraging its proprietary BrainOnly™ platform to enhance drug safety and efficacy. This platform utilizes Brain-Targeting Chimeras (BrainTAC™) to concentrate pharmacological activity in the brain while preventing peripheral toxicities. The technology aims to enable the drugging of established targets and improve the therapeutic index for neurodegenerative conditions and brain cancer.

Novo utilizes AI to rapidly draft legal documents such as demand letters and medical chronologies, significantly reducing the time required from days to minutes. By analyzing client records, Novo enables injury attorneys to create high-quality, compelling narratives that enhance settlement outcomes.

Novoron is developing pharmaceutical therapies that target low-density lipoprotein receptors to enhance nerve regeneration in the central nervous system. Their approach aims to improve outcomes for conditions such as Alzheimer's disease, multiple sclerosis, and spinal cord injuries by restoring the brain's and spinal cord's natural regenerative capabilities.

O is developing an IoT device that visualizes the human circadian clock to enhance individual and organizational performance through data-driven insights. The platform provides actionable recommendations based on sleep data, addressing productivity issues and mental health risks within teams.

ON is an AI chat platform designed for enterprise use, integrating with e-commerce systems like Shopify to enhance customer interactions by providing real-time access to product and order information. This technology addresses the high volume of customer service inquiries, improving site conversions and customer satisfaction while reducing the workload for support agents.

PulseData utilizes patented machine learning models to predict chronic disease progression and identify at-risk patients, enabling healthcare organizations to implement targeted interventions. The platform addresses chronic disease underdiagnosis and undertreatment, improving patient outcomes and reducing healthcare costs.

This company provides an integrated platform for managing post-quantum cryptography (PQC) readiness across enterprise and defense systems. The platform automates cryptographic asset discovery, enables crypto-agility for remediation without system downtime, and generates compliance reports like the Cryptographic Bill of Materials (CBOM). This solution simplifies the transition to quantum-safe encryption while maintaining continuous visibility and control over cryptographic infrastructure.

This startup provides a platform to easily create and monetize APIs from existing datasets without coding. Their platform offers observability, monetization support, and flexible go-to-market tools, enabling businesses to turn data into API products.

The startup develops a drug discovery platform that identifies cancer-specific epitopes in drug-resistant tumors and generates antibodies with atomic-level specificity. This technology enables healthcare researchers to validate therapeutic targets and create immunotherapies that effectively eliminate resistant cancer cells.

Selector offers an AIOps platform that utilizes AI and machine learning to provide real-time incident detection and automated remediation across network and infrastructure environments. By correlating data from various sources, Selector reduces downtime and enhances operational efficiency for large-scale networks.

Talus Bio provides a proprietary platform that quantifies and modulates the regulome—the network of regulatory proteins that control gene expression—directly in live cells using functional proteomics and high‑throughput assays. The system generates millions of compound‑target interaction data points and leverages AI to design chemical libraries that target transcription factors, cofactors, and splicing regulators, enabling pharmaceutical companies to discover and develop therapies against previously undruggable regulatory proteins.

Talusbio operates a marketplace that lets businesses and brand managers acquire premium, verified domain names quickly through a secure checkout. Customers can either purchase a domain outright for a fixed price or choose a lease‑to‑own option with monthly payments, with the platform handling rapid transfer, escrow, and multilingual payment support.

TileDB provides a unified platform for managing and analyzing both structured and unstructured scientific data, enabling teams to catalog, collaborate, and perform large-scale analyses without data silos. This solution enhances the efficiency of drug and target discovery by centralizing diverse data types and facilitating secure collaboration across research teams.